PET/CT measures ENDO-HDR response, may let patients skip chemo

01/30/2013 | AuntMinnie.com (free registration)

PET/CT imaging can determine pathological response in postsurgery patients with stage II and III rectal cancer who underwent short high-dose-rate endorectal brachytherapy prior to surgery, according to results presented at a gastrointestinal cancers meeting. ENDO-HDR may allow patients to avoid chemotherapy before surgery, researchers said. They also hope the method will allow for nonoperative management of many patients.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI